3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
42
130-nm albumin-bound paclitaxel
26
Albumin-Bound Paclitaxel
18
Irinotecan
16
Oxaliplatin
14
Fluorouracil
14
pembrolizumab
13
Nivolumab
13
Magnetic Resonance Spectroscopy
11
Leucovorin
11
Taxes
10
Specimen Handling
9
Biopsy
9
Cisplatin
8
Capecitabine
7
folfirinox
6
Radiotherapy
6
Carboplatin
6
irinotecan sucrosofate
5
durvalumab
5
Ipilimumab
5
Cyclophosphamide
5
olaparib
4
defactinib
4
Surveys and Questionnaires
4
Standard of Care
4
Radiosurgery
4
Immunoglobulin G
4
Disulfides
4
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pancreatic Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled